• Users Online: 247
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
CASE REPORT
Year : 2016  |  Volume : 1  |  Issue : 4  |  Page : 115-117

Management of triple-negative invasive ductal cell carcinoma


1 Department of Surgical Oncology, ARH Medical Centre, Hazard, Kentucky, USA
2 Department of General Surgery, ARH Medical Centre, Hazard, Kentucky, USA

Date of Submission11-Aug-2016
Date of Acceptance23-Nov-2016
Date of Web Publication3-Jan-2017

Correspondence Address:
Assad Salman
Department of Surgical Oncology, ARH Medical Centre, Hazard, Kentucky
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2468-5585.197498

Rights and Permissions
  Abstract 

We reported a case of triple-negative breast cancer who presented to our medical center with a mass in the upper outer quadrant of the left breast. The age of the patient at the time of presentation was 74 years and 8 months. Breast ultrasound revealed a 3.3 cm × 2.7 cm lobulated hypoechoic fibroglandular mass in the upper outer quadrant of the left breast. Core biopsy showed triple-negative (estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2/neu negative) invasive ductal cell cancer of the left breast infiltrating into the skin but no fixation to the chest wall. Neoadjuvant chemotherapy reduced the size of the mass to 2.1 cm × 1.2 cm. Partial mastectomy was then performed along with partial axillary dissection and adjuvant radiotherapy. No recurrence of tumor or any recent breast mass was noted at 1-year follow-up on both mammography and ultrasonography, indicating successful management of triple-negative breast tumor. We conclude that triple-negative breast tumors should be managed with neoadjuvant chemotherapy such as taxanes and cisplatins followed by adjuvant radiotherapy.

Keywords: Chemotherapy, invasive ductal cell carcinoma, partial mastectomy, radiotherapy, triple-negative breast cancer


How to cite this article:
Ahsan Ze, Salman A, Todd TN. Management of triple-negative invasive ductal cell carcinoma. Transl Surg 2016;1:115-7

How to cite this URL:
Ahsan Ze, Salman A, Todd TN. Management of triple-negative invasive ductal cell carcinoma. Transl Surg [serial online] 2016 [cited 2021 Oct 17];1:115-7. Available from: http://www.translsurg.com/text.asp?2016/1/4/115/197498


  Introduction Top


Breast cancer is a heterogeneous disease that encompasses several distinct molecular profiles with different clinical behaviors and responses to therapy. Here, we report the management of a rare case of triple-negative breast cancer (TNBC) with surgery and cytotoxic chemotherapy followed by adjuvant radiotherapy. Tumor size, lymph node status, and grade in conjunction with standardized immunohistochemical assessment of hormone receptors (i.e., estrogen receptor [ER], progesterone receptor [PR]) and human epidermal growth factor receptor 2 (HER2) are currently used in the management of breast cancer patients. Regional management of breast cancer has been used based on the results of randomized controlled trials comparing breast-conserving therapy (i.e., lumpectomy and adjuvant radiation therapy) and modified radical mastectomy. [1],[2],[3] However, among those studies, molecular and biologic heterogeneity of breast cancer outcome was not considered. Indeed, over the past decade, four major molecular subtypes have been introduced through genomic and molecular profiling associated with differences in survival rates and responses to treatment. [4],[5],[6] Most studies have focused on biologic subtyping using ER, PR, and HER2 as biomarkers to approximate these molecular subtypes. [7],[8] TNBCs present poorly differentiated tumors which are characterized by high proliferation rate and increased aggressiveness compared with other subtypes. [9],[10],[11],[12] TNBCs are not benefited from hormonal or trastuzumab-based therapies because of the absence of target receptors such as ER, PR, and HER2. Hence, conventional cytotoxic chemotherapy followed by adjuvant radiotherapy is the standard of care for these patients. The paucity of therapeutic options emphasizes the urgent need to optimize the current management of patients with TNBC and reduce their risk of locoregional recurrence.


  Case Report Top


A female patient aged 74 years and 8 months presented to the hospital with a mass, measuring 3.3 cm × 2.7 cm, on the upper outer quadrant of the left breast, measured from the nipple laterally and including the central portion of the breast. Infiltration into the skin was observed with no fixation to the chest wall. Breast ultrasound done showed 3.3 cm × 2.7 cm lobulated hypoechoic mass, and core biopsy showed invasive ductal cell cancer of the left breast. Case history showed a diagnosis of actinic keratosis on both cheeks of face, for which she was prescribed topical fluorouracil and advised to use moisturizers. She is a known hypertensive patient and on antihypertensives for 25 years. She is alcoholic and smoker and her counseling to quit smoking and alcohol consumption was done accordingly. Family history showed colorectal cancer in three family members and breast cancer in a paternal aunt. The histopathologic findings of the core needle biopsy showed invasive ductal cell carcinoma, ER-negative, PR-negative, and HER2-neu-negative or triple-negative tumor. Immunohistochemical examination and/or fluorescence in situ hybridization (FISH) was used to determine ER, PR, and HER2-neu status. ER and PR results were considered positive with ≥1% positively staining cells. HER2-neu was considered positive with either 3+ immunoreactivity or amplification by FISH. The patient was on triamterene-HCTZ (50-75 mg), simvastatin (20 mg), and ranitidine HCL 150 mg, with known allergies to acetaminophen and loratadine. Mammogram done 6 months after breast cancer diagnosed and treated with neoadjuvant chemotherapy showed no calcifications with the Breast Imaging Reporting and Data System 1. Ultrasound showed fibroglandular tissue in the upper outer quadrant of the left breast showing complex nodule, with central cystic area measuring about 2.1 cm × 1.2 cm and a cluster of small cysts within. Another well-circumscribed small nodule showing posterior shadowing representing area of calcification was observed.

Partial mastectomy procedure was then performed which involved placing a crescent and batwing incision and elevating superior and inferior flaps around the area of the lesion which was localized sonographically on the previous day. The specimen was then taken to a back table where the margins were painted with Vector kit and then the radiopaque markers were placed on the margins. It was then taken to the radiology department where specimen radiograph was obtained showing a good acquisition of three clips that had been placed preoperatively, one each at the upper and lower edges of the tumor and one in the center. The wound was then closed after elevating the breast tissue off the chest wall and closing the lumpectomy site with 3-0 Vicryl suture in layers. A clip was placed at the center of the tumor. The skin was closed with 3-0 Vicryl followed by 2-0 Quill. Three-dimensional conformal accelerated partial breast irradiation was used for postmastectomy radiotherapy to the left breast. No recurrence of tumor or any recent breast mass was noted at 1-year follow-up on both mammography and ultrasonography, indicating the successful management of triple-negative breast tumor.


  Discussion Top


Patients with TNBC are not benefited from hormonal or trastuzumab-based therapies because of the absence of target receptors such as ER, PR, and HER2. Hence, the available treatment options are surgery, chemotherapy, and radiotherapy, individually or in combination. New targeted therapeutic drugs against cell surface receptors such as epidermal growth factor receptor (EGFR) and c-Kit are currently under consideration. Livasy CA et al. [13] reported the presence of c-Kit in 31% of basal-like tumor cells and 11% of nonbasal-like tumor cells. Our patient had BRCA1-deficient triple-negative tumor. Some recent reports suggest that because BRCA1-deficient breast tumors share the characteristics of basal-like tumors, the therapeutic management that targets basal-like tumors should also be highly effective in the treatment of BRCA1-deficient breast cancer and triple-negative tumors. [14]

Genomic instability and predisposition to carcinogenesis due to mutations in the BRCA1 gene are the consequences of defects in DNA repair. This process could be related to the control of proliferation in BRCA1-related, triple-negative, and basal-like tumor cells. Results from several in vitro studies have shown that breast tumor cells with BRCA1 mutations are extremely sensitive to drugs that induce cross-links (mitomycin-C and platinum) and single- and double-strand breaks (etoposide and bleomycin) in DNA. [15],[16] Base-excision repair pathways with poly ADP-ribose polymerase 1 (PARP1) enzyme are used in single-strand DNA breaks. Cells without BRCA1 were shown to be incapable of repairing DNA strand breaks, and apoptotic processes were enhanced by the inhibition of PARP1. [17],[18],[19] Hence, BRCA1 null cells were shown to be more sensitive to chemo- and radio-therapies. In contrast, these cells were shown to be resistant to mitotic-spindle targeting drugs such as taxanes and vinorelbine. [20] Targeted therapy can be used to dysfunction BRCA1 and PARP1 pathways in a significant subgroup of triple-negative and basal-like breast tumors. [18],[21] In addition, local radiotherapy may be of significant benefit for patients with triple-negative cancer because ionizing radiations also provoke DNA strand breaks. Drugs such as carboplatin, cisplatin, PARP1 inhibitors, and docetaxel could be valuable in the treatment of patients with advanced triple-negative cancers. Approximately, 66% of breast cancer patients with triple-negative and basal-like tumor cells have been reported to express EGFR. [13],[22],[23] Inhibition of EGFR might be an useful therapeutic strategy. Clinical trials evaluating the efficacy of humanized anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors in patients with TNBC are currently under way. [24]

It is instrumental to determine the ER, PR, and HER2 status for TNBC diagnosis; therefore, it will be plausible to demonstrate the immunohistochemistry results of ER, PR, and HER2 as well as the HER2 FISH result. Given that the patient has a family history and BRCA screening has been performed, presenting the screening result will be required if further treatment based on BRCA status is proposed. The mammography and ultrasonography performed before treatment and at 1-year follow-up shows the successful management of this case.

In conclusion, neoadjuvant cytotoxic chemotherapy followed by adjuvant radiotherapy is the standard of care for patients with TNBCs since endocrine and HER2-targeted therapies cannot be offered. We conclude that the triple-negative breast tumors should be managed with neoadjuvant chemotherapy, with drugs such as taxanes, cisplatins, and carboplatins followed by surgery and adjuvant radiotherapy as it is clear that the targeted therapy has no role.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Onitilo AA, Engel JM, Stankowski RV, Doi SA. Survival comparisons for breast conserving surgery and mastectomy revisited: Community experience and the role of radiation therapy. Clin Med Res 2015;13 (2):65-73.  Back to cited text no. 1
    
2.
Brown LC, Mutter RW, Halyard MY. Benefits, risks, and safety of external beam radiation therapy for breast cancer. Int J Womens Health 2015;7:449-58.  Back to cited text no. 2
    
3.
Schnitt SJ. Classification and prognosis of invasive breast cancer: From morphology to molecular taxonomy. Mod Pathol 2010;23 Suppl 2:S60-4.  Back to cited text no. 3
    
4.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100 (14):8418-23.  Back to cited text no. 4
    
5.
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100 (18):10393-8.  Back to cited text no. 5
    
6.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006;295 (21):2492-502.  Back to cited text no. 6
    
7.
Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer CE Jr., Wickerham DL, Costantino JP, Wolmark N. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 2009;27 (15):2466-73.  Back to cited text no. 7
    
8.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353 (16):1659-72.  Back to cited text no. 8
    
9.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365 (14):1273-83.  Back to cited text no. 9
    
10.
Zhang MJ, Zhang X, Scheike TH. Modeling cumulative incidence function for competing risks data. Expert Rev Clin Pharmacol 2008;1 (3):391-400.  Back to cited text no. 10
    
11.
Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24 (36):5652-7.  Back to cited text no. 11
    
12.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13 (15):4429-34.  Back to cited text no. 12
    
13.
Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19 (2):264-71.  Back to cited text no. 13
    
14.
Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med 2015;12 (2):106-16.  Back to cited text no. 14
    
15.
Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, Bulotta A, Neri P, Caraglia M, Tagliaferri P. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 2009;8 (7):648-53.  Back to cited text no. 15
    
16.
Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: Clinical and prognostic implications. Eur J Cancer 2009;45 Suppl 1:27-40.  Back to cited text no. 16
    
17.
Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005;5 (4):388-93.  Back to cited text no. 17
    
18.
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434 (7035):917-21.  Back to cited text no. 18
    
19.
Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005;70:139-48.  Back to cited text no. 19
    
20.
Yuanming L, Lineng Z, Baorong S, Junjie P, Sanjun C. BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer. BMC Cancer 2013;13:103.  Back to cited text no. 20
    
21.
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumors with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434 (7035):913-7.  Back to cited text no. 21
    
22.
Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109 (1):25-32.  Back to cited text no. 22
    
23.
Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, Lambros MB, Pereira EM, Nesland JM, Lakhani SR, Schmitt FC. Metaplastic breast carcinomas exhibit EGFR, but not HER2 NEU, gene amplification and overexpression: Immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005;7 (6):R1028-35.  Back to cited text no. 23
    
24.
Isakoff SJ. Triple-negative breast cancer: Role of specific chemotherapy agents. Cancer J 2010;16 (1):53-61.  Back to cited text no. 24
    




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Case Report
Discussion
References

 Article Access Statistics
    Viewed2607    
    Printed148    
    Emailed0    
    PDF Downloaded239    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]